Accuray (ARAY)
(Real Time Quote from BATS)
$2.14 USD
-0.07 (-3.17%)
Updated Apr 19, 2024 03:02 PM ET
3-Hold of 5 3
B Value F Growth B Momentum D VGM
Price, Consensus and EPS Surprise
ARAY 2.14 -0.07(-3.17%)
Will ARAY be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ARAY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ARAY
Atossa (ATOS) Reports Positive Results From EVANGELINE Study
Accuray's (ARAY) CyberKnife Improves Prostate Cancer Treatment
ARAY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why You Should Retain Accuray (ARAY) Stock for Now
Accuray (ARAY) Up 1.6% Since Last Earnings Report: Can It Continue?
Three Reasons to Retain Accuray (ARAY) Stock in Your Portfolio
Other News for ARAY
Accuray Expands Global Training Center Network With Opening of New Facility in Genolier, Switzerland
Accuray to Report Third Quarter Fiscal 2024 Financial Results on May 1, 2024
Slone Partners Places Chris Raanes as CEO at Magnetic Insight
Accuray Getting Very Little Love Ahead Of A Coming Revenue Ramp
New Data from Two Clinical Studies Indicate High-Risk and Recurrent Prostate Cancers Can be Effectively Treated in 5 Days Using the Accuray CyberKnife® System